A review of Acinetobacter baumannii as a highly successful pathogen in times of war

Laboratory Medicine

Volumn 41, Issue 11, 2010, Pages 649-657

  Camp, Callie ^a   Tatum, Owatha L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Acinetobacter baumannii; Drug resistance; Microbiology; Molecular diagnostics; Nosocomial; Pathogen transmission

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; APRAMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BETAMICIN; CARBAPENEM; CEPHALOSPORIN; GENTAMICIN; KANAMYCIN; LIVIDOMYCIN; MONOBACTAM; NEOMYCIN; OUTER MEMBRANE PROTEIN; PAROMOMYCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; STREPTOMYCIN; TEMOCILLIN; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AFGHANISTAN; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BATTLE INJURY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTEGRON; INTENSIVE CARE; IRAQ; LABORATORY DIAGNOSIS; MILITARY MEDICINE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; REVIEW; SOLDIER; TRANSPOSON;

ACINETOBACTER BAUMANNII;

EID: 78449309151     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LM90IJNDDDWRI3RE     Document Type: Review

References (69)

1. Nemec A, Musílek M, Maixnerová M, et al. Acinetobacter beijerinckii sp. nov. and Acinetobacter gyllenbergii sp. nov., haemolytic organisms isolated from humans. Int J Syst Evol Microbiol. 2009;59:118-124.
2. Towner KJ. Acinetobacter: An old friend, but a new enemy. J Hosp Infect. 2009;73:355-363.
3. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol. 1991;29:277-282.
4. Rajamohan G, Srinivasan VB, Gebreyes WA. Biocide-tolerant multidrug-resistant Acinetobacter baumannii clinical strains are associated with higher biofilm formation. J Hosp Infect. 2009;73:287-289.
5. Kulah C, Aktas E, Comert F, et al. Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan WalkAway, Vitek 2); high error rates with Microscan WalkAway. BMC Infect Dis. 2009;9:30.
6. Erbay A, Idil A, Gözel MG, et al. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34:575-579.
7. Struelens MJ, Carlier E, Maes N, et al. Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: Outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. J Hosp Infect. 1993;25:15-32.
8. Centers for Disease Control. Overview of Drug-resistant Acinetobacter Infections in Healthcare Settings. Centers for Disease Control and Prevention. Available at: www.cdc.gov/ncidod/dhqp/ar-acinetobacter.html. Accessed October 26, 2009.
9. Davis KA, Moran KA, McAllister CK, et al. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis. 2005;11:1218-1224.
10. Oncül O, Keskin O, Acar HV, et al. Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect. 2002;51:47-51.
11. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2007;28:1247-1254.
12. Van Looveren M, Goossens H; ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect. 2004;10:684-704.
13. Tomaras AP, Dorsey CW, McQueary C, et al. Molecular basis of acinetobacter virulence and pathogenicity. In: Gerischer U, ed. Acinetobacter Molecular Biology. 1st ed. Ulm, Germany: Caister Academic Press; 2008.
14. Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2006;50:4114-4123.
15. Scott P, Deye G, Srinivasan A, et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis. 2007;44:1577-1584.
16. Zarrilli R, Crispino M, Bagattini M, et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol. 2004;42:946-953.
17. Hardaway RM. 200 years of military surgery. Injury. 1999;30:387-397.
18. Kiehn CL. Progress attained in the search for the primary healing of gunshot wounds of the extremities in the ETO in World War II. Bull N Y Acad Med. 1989;65:866-878.
19. Wannamaker GT, Pulaski EJ. Pyogenic neurosurgical infections in Korean battle casualties. J Neurosurg. 1958;15:512-518.
20. DeWaal HL. Wound infection. A preliminary note on a combined clinical and bacteriological investigation of 708 wounds. Edinburgh Med J. 1943;L:577-589.
21. McKissock W, Wright J, Miles AA. The reduction of hospital infection of wounds. A controlled experiment. British Med J. 1941;2:375-377.
22. Miles AA, Schwabacher H, Cunliffe AC. Hospital infection of war wounds. British Med J. 1940;2:855-859, 895-900.
23. Department of Defense. Directorate for information operations and reports. Available at: www.dior.whs.mil/mmid/casualty/castop.htm. Accessed November 3, 2009.
24. Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004;19;53:1063-1066.
25. Gawande A. Casualties of war - Military care for the wounded from Iraq and Afghanistan. N Engl J Med. 2004;351:2471-2475.
26. Mazurek MT, Ficke JR. The scope of wounds encountered in casualties from the global war on terrorism: From the battlefield to the tertiary treatment facility. J Am Acad Orthop Surg. 2006;14:S18-S23.
27. Getchell-White SI, Donowitz LG, Gröschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: Evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol. 1989;10:402-407.
28. Jawad A, Snelling AM, Heritage J, et al. Exceptional desiccation tolerance of Acinetobacter radioresistens. J Hosp Infect. 1998;39:235-240.
29. Catalano M, Quelle LS, Jeric PE, et al. Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J Hosp Infect. 1999;42:27-35.
30. McPherson III J, Yacoub A, Runner R, et al. Effectiveness of halogen-based disinfectants against Acinetobacter baumannii: Wound care and environmental decontamination. Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia Department of Clinical Investigation and Medicine, 2006.
31. Naas T, Coignard B, Carbonne A, et al. VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France. Emerg Infect Dis. 2006;12:1214-1222.
32. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The preantibiotic era has returned. Arch Intern Med. 2002;162:1515-1520.
33. Siegel JD, Rhinehart E, Jackson M, et al. Management of multi drug resistant organisms in healthcare settings, 2006. Centers for Disease Control and Prevention. 2006.
34. Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: Experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis. 2002;34:499-503.
35. Aygün G, Demirkiran O, Utku T, et al. Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect. 2002;52:259-262.
36. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol. 2003;24:284-295.
37. Cefai C, Richards J, Gould FK, et al. An outbreak of Acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect. 1990;15:177-182.
38. Jawad A, Heritage J, Snelling AM, et al. Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J Clin Microbiol. 1996;34:2881-2887.
39. Wendt C, Dietze B, Dietz E, et al. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol. 1997;35:1394-1397.
40. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45:999-1007.
41. Walsh SE, Maillard JY, Russell AD, et al. Development of bacterial resistance to several biocides and effects on antibiotic susceptibility. J Hosp Infect. 2003;55:98-107.
42. Turton JF, Kaufmann ME, Gill MJ, et al. Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict. J Clin Microbiol. 2006;44:2630-2634.
43. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:S49-S56.
44. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: Beta-lactams in peril! Curr Opin Microbiol. 2005;8:518-524.
45. Naas T, Bogaerts P, Bauraing C, et al. Emergence of PER and VEB extended-spectrum beta-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother. 2006;58:178-182.
46. Schirmer T. General and specific porins from bacterial outer membranes. J Struct Biol. 1998;121:101-109.
47. Obara M, Nakae T. Mechanisms of resistance to beta-lactam antibiotics in Acinetobacter calcoaceticus. J Antimicrob Chemother. 1991;28:791-800.
48. del Mar Tomás M, Beceiro A, Pérez A, et al. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49:5172-5175.
49. Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46:1254-1263.
50. Afzal-Shah M, Villar HE, Livermore DM. Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina. J Antimicrob Chemother. 1999;43:127-131.
51. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148-165.
52. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2001;45:583-588.
53. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs. 2002;3:218-224.
54. Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr Pharm Biotechnol. 2002;3:117-127.
55. Kulah C, Aktas E, Comert F, et al. Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan WalkAway, Vitek 2); high error rates with Microscan WalkAway. BMC Infect Dis. 2009;9:30.
56. bioMérieux. Vitek 2 healthcare. Available at: http://www. biomerieux-usa.com/servlet/srt/bio/usa/. Accessed June 4, 2009.
57. O'Hara CM, Miller JM. Ability of the MicroScan rapid gram-negative ID type 3 panel to identify nonenteric glucose-fermenting and nonfermenting gram-negative bacilli. J Clin Microbiol. 2002;40:3750-3752.
58. Schwartz DC, Cantor CR. Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. Cell. 1984;37:67-75.
59. Misbah S, Hassan H, Yusof MY, et al. Genomic species identification of Acinetobacter of clinical isolates by 16S rDNA sequencing. Singapore Med J. 2005;46:461-464.
60. Koh TH, Sng LH, Wang GC, et al. IMP-4 and OXA beta-lactamases in Acinetobacter baumannii from Singapore. J Antimicrob Chemother. 2007;59:627-632.
61. Docquier JD, Lamotte-Brasseur J, Galleni M, et al. On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother. 2003;51:257-266.
62. Shaw KJ, Rather PN, Hare RS, et al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993;57:138-163.
63. Lambert T, Gerbaud G, Bouvet P, et al. Dissemination of amikacin resistance gene aphA6 in Acinetobacter spp. Antimicrob Agents Chemother. 1990;34:1244-1248.
64. Nemec A, Dolzani L, Brisse S, et al. Diversity of aminoglycoside- resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol. 2004;53:1233-1240.
65. Rubin J, Walker RD, Blickenstaff K, et al. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. Vet Microbiol. 2008;131:164-172.
66. Jones LA, McIver CJ, Kim MJ, et al. The aadB gene cassette is associated with blaSHV genes in Klebsiella species producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2005;49:794-797.
67. Marchand I, Damier-Piolle L, Courvalin P, et al. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother. 2004;48:3298-3304.
68. De Wals PY, Doucet N, Pelletier JN. High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized â-lactam recognition. Protein Sci. 2009;18:147-160.
69. Tzouvelekis LS, Bonomo RA. SHV-type beta-lactamases. Curr Pharm Des. 1999;5:847-864.